RESUMEN
PIP: A large increase in the number of falciparum malaria cases imported into the UK was reported to the malaria reference laboratory in the first quarter of 1998. Contributory factors were unusually heavy rains in east Africa and a reduction in the use of the most effective antimalarial drug, mefloquine. There was also an increase in the number of cases of severe malaria in the UK. During December 1997 and January 1998, the Hospital for Tropical Diseases, London, treated 5 patients for severe malaria and gave advice on 20 more patients with malaria who had been admitted to intensive care units throughout England. 4 of the severe cases treated at the hospital are reported. In 3 of those 4 cases, incorrect, misleading, or inadequate advice was given by health care professionals. Media coverage of the adverse effects of antimalarial drugs has contributed to confusion about prophylactic regimens among both health care professionals and the public. The incidence of falciparum malaria among travellers who do not take prophylactic drugs is about 0.6% in east Africa and 3.5% in west Africa over a 2-week travel period. Travellers need to take measures to avoid being bitten by mosquitoes and should be taught to promptly seek medical help if they develop a fever while abroad or after they return. Moreover, using any one of the recommended prophylactic regimens is better than not using a potent regimen or no prophylaxis at all. Mefloquine is 90% protective against malaria in sub-Saharan Africa. While the efficacy of proguanil and chloroquine in 1987 was about 70% in west Africa and 50% in east Africa, those levels are now probably lower. The side effects of antimalarial drugs are discussed.^ieng
Asunto(s)
Antimaláricos/efectos adversos , Malaria/prevención & control , Adulto , Cloroquina/efectos adversos , Brotes de Enfermedades , Femenino , Humanos , Malaria/epidemiología , Masculino , Mefloquina/efectos adversos , Persona de Mediana Edad , Proguanil/efectos adversos , Factores de Riesgo , Viaje , Reino Unido/epidemiologíaRESUMEN
Diagnosing the febrile returned traveller is a problem faced ever more frequently by the practising physician. This article aims to provide a structured approach to what may, at first, seem a complex issue.
Asunto(s)
Fiebre/etiología , Viaje , Diagnóstico Diferencial , Fiebre/diagnóstico , Humanos , Anamnesis , Examen Físico , Medicina TropicalRESUMEN
To determine whether a particular ideal orthodontic arch form could be identified, the mandibular dental casts of 30 untreated normal cases, 30 Class I nonextraction cases, and 30 Class II nonextraction cases were examined. Following computerized digitizing and the use of a mathematic function called polynomial of the fourth degree, arch forms were generated for each sample and then compared to 17 commercially produced arch forms. Results showed that no particular arch form predominated in any of the three samples. A shape representing a combination of the "Par" and "Vari-Simplex" arch forms approximated to only 50% of the cases in the three samples. The remaining 50% of the cases displayed a wide variety of arch forms. Cases that had changes in arch form during nonextraction treatment frequently were not stable; almost 70% showed significant long-term posttreatment changes. Customizing arch forms appears to be necessary in many cases to obtain optimum long-term stability because of the great individual variability in arch form found in this study.
Asunto(s)
Arco Dental/anatomía & histología , Procesamiento de Imagen Asistido por Computador , Maloclusión/terapia , Mandíbula/anatomía & histología , Adolescente , Niño , Oclusión Dental , Diseño de Equipo , Femenino , Humanos , Masculino , Maloclusión/patología , Modelos Dentales , Aparatos OrtodóncicosRESUMEN
Five hundred and ninety-four patients were consecutively admitted to an infectious disease unit over a 2-year period with a referral diagnosis of acute gastroenteritis or food poisoning. In 175 (29%) patients, gastrointestinal symptoms were associated with a condition other than gastrointestinal infection. Non-infective gastrointestinal disease was present in 90 patients, systemic infection in 50 and systemic disease in 35. Four illustrative case histories are presented to emphasize the need for a high index of suspicion if diseases such as malaria, septicaemia or appendicitis are not to be missed.
Asunto(s)
Gastroenteritis/diagnóstico , Enfermedad Aguda , Adulto , Anciano , Animales , Apendicitis/diagnóstico , Diagnóstico Diferencial , Femenino , Enfermedades Gastrointestinales/diagnóstico , Humanos , Malaria/diagnóstico , Masculino , Persona de Mediana Edad , Plasmodium falciparum , Sepsis/diagnóstico , Infecciones Urinarias/diagnósticoRESUMEN
Pneumocystis carinii is a common cause of pneumonia in individuals who are immunosuppressed by HIV infection. Use of molecular biological techniques show that P. carinii is a fungus and that infection in man is not a zoonosis. Invasive tests such as sputum induction or bronchoscopy are used to make the diagnosis of P. carinii pneumonia. Life long primary prophylaxis is given to HIV positive individuals with CD4+ lymphocyte counts < 0.20 x 10(9)/L or a CD4: total lymphocyte ratio of < 1.5, constitutional symptoms, or with other AIDS defining diseases. Secondary prophylaxis is given after a first episode to prevent a recurrence. First choice for primary and secondary prophylaxis is oral co-trimoxazole 960 mg od or three times a week. In patients who are intolerant to co-trimoxazole, nebulised pentamidine or dapsone (with or without pyrimethamine) are second and third choices. In a patient with acute PCP disease, severity should be assessed using clinical, radiographic and blood gas criteria as those with moderate or severe disease will benefit from adjuvant glucocorticoids. Co-trimoxazole (120 mg/kg/day in divided doses for 21 days) is first choice therapy for PCP of all degrees of severity. In patients who fail to respond to co-trimoxazole or who are intolerant to it, second line treatment is iv pentamidine in those with severe disease and oral dapsone with trimethoprim, oral clindamycin with primaquine or iv pentamidine in those with mild or moderately severe disease.